Recently Hasegawa group also reported SGLT2 was elevated during early stages of DKD, which could upregulate intracellular glucose levels in proximal tubules and subsequently decrease SIRT1 expression whereas SGLT2 inhibitors preserved SIRT1 expression (102). The gene discussed is SIRT1; the disease is diabetic kidney disease.